

Analysis of Covariance (ANCOVA) of Change from Baseline in  
Fasting Glucose (mmol/L) at Week 24 (LOCF)  
Efficacy Analysis Population

|                                                                                                                                   | Baseline |            | Week 24 (LOCF)                              |            | Change from Baseline |             |                               |
|-----------------------------------------------------------------------------------------------------------------------------------|----------|------------|---------------------------------------------|------------|----------------------|-------------|-------------------------------|
| Treatment Group                                                                                                                   | N        | Mean (SD)  | N                                           | Mean (SD)  | N                    | Mean (SD)   | LS Mean (95% CI) <sup>a</sup> |
| Placebo                                                                                                                           | 79       | 5.7 (2.23) | 79                                          | 5.6 (1.65) | 79                   | -0.0 (2.32) | 0.07 (-0.26, 0.41)            |
| Xanomeline Low Dose                                                                                                               | 79       | 5.4 (0.95) | 79                                          | 5.4 (1.06) | 79                   | -0.1 (1.02) | -0.11 (-0.44, 0.23)           |
| Xanomeline High Dose                                                                                                              | 74       | 5.4 (1.37) | 74                                          | 5.8 (2.21) | 74                   | 0.4 (1.65)  | 0.39 (0.04, 0.74)             |
| Pairwise Comparison                                                                                                               |          |            | Difference in LS Mean (95% CI) <sup>a</sup> |            |                      |             | p-Value <sup>b</sup>          |
| Xanomeline Low Dose vs. Placebo                                                                                                   |          |            | -0.18 (-0.65, 0.30)                         |            |                      |             | 0.4670                        |
| Xanomeline High Dose vs. Placebo                                                                                                  |          |            | 0.32 (-0.17, 0.80)                          |            |                      |             | 0.2004                        |
| <sup>a</sup> LS means and differences in LS means are based on an ANCOVA model with treatment and baseline glucose as covariates. |          |            |                                             |            |                      |             |                               |
| <sup>b</sup> p-values are from the ANCOVA model testing treatment effects (overall F-test p-value: 0.0000).                       |          |            |                                             |            |                      |             |                               |
| LOCF (Last Observation Carried Forward) approach is used for missing Week 24 values.                                              |          |            |                                             |            |                      |             |                               |
| ANCOVA = Analysis of Covariance; CI = Confidence Interval; LS = Least Squares; SD = Standard Deviation                            |          |            |                                             |            |                      |             |                               |

Source: ADLBC Analysis Dataset  
Analysis conducted: 06NOV2025  
Statistical software: Python (statsmodels)